News

Merge Healthcare claimed that the new CIMS solution is the first open platform in the industry that allows organisations involved in clinical trials to transparently execute the imaging

ViroStatics claimed that AV-HALTS are a new class of drugs that combine direct anti-viral activity with a reduction in the chronically elevated immune system activation that is now

Cell Therapeutics’ PIX301 trial analyses demonstrated that patients who achieved a complete response (CR)/unconfirmed complete response (CRu) to Pixuvri had up to a 63% probability of being alive

Boston Scientific said that the Taxus Element Stent System is the company’s third-generation drug-eluting stent (DES) technology and incorporates a platinum chromium alloy with an innovative stent design

As per the terms of the agreement, Danone is expected to pay an amount of approximately $62m in cash to MNI’s shareholders for the acquisition of 100% of

The advisory committee of FDA, that reviews and decides whether to approve a new treatment, has voted that FTY720 demonstrated substantial efficacy in treating relapsing remitting MS and

Benlysta is being developed by GlaxoSmithKline (GSK) and HGS under a co-development and commercialisation agreement entered into in 2006. Benlysta is an investigational human monoclonal antibody drug. Both

WaferGen said that the first panel, SmartChip Human MicroRNA Panel, provides a comprehensive human microRNA profile of more than 800 microRNAs on a single SmartChip and usefull with

Repros is expected to be allowed to run a single study under the new partial clinical hold status. The new low dose study is designed to explore both